Cargando…
Clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review
BACKGROUND: Clinical significance in a randomized controlled trial (RCT) can be determined using the minimal clinically important difference (MCID), which should inform the delta value used to determine sample size. The primary objective was to assess clinical significance in the pediatric oncology...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173909/ https://www.ncbi.nlm.nih.gov/pubmed/30290839 http://dx.doi.org/10.1186/s13063-018-2925-8 |
_version_ | 1783361210826096640 |
---|---|
author | Howard, A. Fuchsia Goddard, Karen Rassekh, Shahrad Rod Samargandi, Osama A Hasan, Haroon |
author_facet | Howard, A. Fuchsia Goddard, Karen Rassekh, Shahrad Rod Samargandi, Osama A Hasan, Haroon |
author_sort | Howard, A. Fuchsia |
collection | PubMed |
description | BACKGROUND: Clinical significance in a randomized controlled trial (RCT) can be determined using the minimal clinically important difference (MCID), which should inform the delta value used to determine sample size. The primary objective was to assess clinical significance in the pediatric oncology randomized controlled trial (RCT) treatment literature by evaluating: (1) the relationship between the treatment effect and the delta value as reported in the sample size calculation, and (2) the concordance between statistical and clinical significance. The secondary objective was to evaluate the reporting of methodological attributes related to clinical significance. METHODS: RCTs of pediatric cancer treatments, where a sample size calculation with a delta value was reported or could be calculated, were systematically reviewed. MEDLINE, EMBASE, and the Cochrane Childhood Cancer Group Specialized Register through CENTRAL were searched from inception to July 2016. RESULTS: RCTs (77 overall; 11 and 66), representing 95 (13 and 82) randomized questions were included for non-inferiority and superiority RCTs (herein, respectively). The minority (22.1% overall; 76.9 and 13.4%) of randomized questions reported conclusions based on clinical significance, and only 4.2% (15.4 and 2.4%) explicitly based the delta value on the MCID. Over half (67.4% overall; 92.3 and 63.4%) reported a confidence interval or standard error for the primary outcome experimental and control values and 12.6% (46.2 and 7.3%) reported the treatment effect, respectively. Of the 47 randomized questions in superiority trials that reported statistically non-significant findings, 25.5% were possibly clinically significant. Of the 24 randomized questions in superiority trials that were statistically significant, only 8.3% were definitely clinically significant. CONCLUSIONS: A minority of RCTs in the pediatric oncology literature reported methodological attributes related to clinical significance and a notable portion of statistically insignificant studies were possibly clinically significance. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-018-2925-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6173909 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61739092018-10-15 Clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review Howard, A. Fuchsia Goddard, Karen Rassekh, Shahrad Rod Samargandi, Osama A Hasan, Haroon Trials Review BACKGROUND: Clinical significance in a randomized controlled trial (RCT) can be determined using the minimal clinically important difference (MCID), which should inform the delta value used to determine sample size. The primary objective was to assess clinical significance in the pediatric oncology randomized controlled trial (RCT) treatment literature by evaluating: (1) the relationship between the treatment effect and the delta value as reported in the sample size calculation, and (2) the concordance between statistical and clinical significance. The secondary objective was to evaluate the reporting of methodological attributes related to clinical significance. METHODS: RCTs of pediatric cancer treatments, where a sample size calculation with a delta value was reported or could be calculated, were systematically reviewed. MEDLINE, EMBASE, and the Cochrane Childhood Cancer Group Specialized Register through CENTRAL were searched from inception to July 2016. RESULTS: RCTs (77 overall; 11 and 66), representing 95 (13 and 82) randomized questions were included for non-inferiority and superiority RCTs (herein, respectively). The minority (22.1% overall; 76.9 and 13.4%) of randomized questions reported conclusions based on clinical significance, and only 4.2% (15.4 and 2.4%) explicitly based the delta value on the MCID. Over half (67.4% overall; 92.3 and 63.4%) reported a confidence interval or standard error for the primary outcome experimental and control values and 12.6% (46.2 and 7.3%) reported the treatment effect, respectively. Of the 47 randomized questions in superiority trials that reported statistically non-significant findings, 25.5% were possibly clinically significant. Of the 24 randomized questions in superiority trials that were statistically significant, only 8.3% were definitely clinically significant. CONCLUSIONS: A minority of RCTs in the pediatric oncology literature reported methodological attributes related to clinical significance and a notable portion of statistically insignificant studies were possibly clinically significance. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13063-018-2925-8) contains supplementary material, which is available to authorized users. BioMed Central 2018-10-05 /pmc/articles/PMC6173909/ /pubmed/30290839 http://dx.doi.org/10.1186/s13063-018-2925-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Howard, A. Fuchsia Goddard, Karen Rassekh, Shahrad Rod Samargandi, Osama A Hasan, Haroon Clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review |
title | Clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review |
title_full | Clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review |
title_fullStr | Clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review |
title_full_unstemmed | Clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review |
title_short | Clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review |
title_sort | clinical significance in pediatric oncology randomized controlled treatment trials: a systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6173909/ https://www.ncbi.nlm.nih.gov/pubmed/30290839 http://dx.doi.org/10.1186/s13063-018-2925-8 |
work_keys_str_mv | AT howardafuchsia clinicalsignificanceinpediatriconcologyrandomizedcontrolledtreatmenttrialsasystematicreview AT goddardkaren clinicalsignificanceinpediatriconcologyrandomizedcontrolledtreatmenttrialsasystematicreview AT rassekhshahradrod clinicalsignificanceinpediatriconcologyrandomizedcontrolledtreatmenttrialsasystematicreview AT samargandiosamaa clinicalsignificanceinpediatriconcologyrandomizedcontrolledtreatmenttrialsasystematicreview AT hasanharoon clinicalsignificanceinpediatriconcologyrandomizedcontrolledtreatmenttrialsasystematicreview |